How does insurance affect wegovy and ozempic copays?

WeGovy and Ozempic are two prescription medications used to treat type 2 diabetes. WeGovy is a combination of two medications, tirzepatide and bupropion, while Ozempic is a medication containing semaglutide [1]. Insurance coverage, including copays, can significantly impact patients' access to these medications.

Currently, WeGovy is not yet approved for any indication in the United States and its availability and pricing are not available. However, Ozempic, as of 2023, is approved for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes [2] or for chronic weight management in adults with obesity who have at least one weight-related condition [3].

According to some sources including drugpatentwatch.com, the copay assistance programs for these medications might vary. The manufacturer of Ozempic, Novo Nordisk, offers a savings program that can reduce the copay to $10 or less for eligible patients [4].

The copay for Ozempic can range anywhere from $1 to $50, depending on the insurance plan and location, as per a 2023 report from DrugPatentWatch.com [4]. Insurance companies, in turn, often have different pricing structures and reimbursement policies for prescription medications.

Insurance coverage can also impact the copays for WeGovy and Ozempic. Some insurance plans may not cover these medications as they are still relatively new to market, or they may have varying degrees of coverage depending on the specific insurance plan and policy requirements.

Patients with insurance policies that cover these medications may be able to receive more affordable copays. For example, a patient with a plan that has a tier 2 coverage may pay less for one of these medications compared to a patient with a plan that has a tier 3 coverage https://www.goodrx.com provides information on medication prices, coverage, and copay assistance programs, including for Ozempic.